Can regenerative medicine help with back pain from worn spinal discs?

Research into cell-based treatments for degenerative disc disease advanced in 2025 and 2026, including a large 36-month Phase III trial and FDA fast-track designations for intradiscal cell products. It is a genuinely active area of study, which is why back pain generates so many questions about regenerative options.

These treatments remain investigational, and the most instructive trials show that structural changes do not always translate into symptom relief. A disc that looks different on imaging does not guarantee that a person feels better, and that gap is exactly why this field has not yet settled into standard care.

At our clinic, back pain starts with understanding what is actually driving it, whether a disc, a joint, or a muscle, before any treatment is discussed. A careful evaluation separates the causes that respond to conservative care from those where a regenerative conversation may be reasonable, and it never skips the diagnosis on the way to an injection.